Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)
In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. In a randomized trial, we tested whether similar improvements would be observed when daratumumab was added to the bortezomib, cyclophosphamide, and dexametha...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | английский |
| Опубликовано: |
2024
|
| Online-ссылка: | https://doi.org/10.1182/bloodadvances.2023012539 https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012539/2225304/bloodadvances.2023012539.pdf |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|